NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
April 14, 2023 20:19 ET
|
NKGen Biotech
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.’s non-genetically...
Global Natural Killer NK Cell Therapy Market Clinical Trials Companies Insight 2023
March 20, 2023 02:22 ET
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023 Report Highlights: Global Natural Killer (NK)...
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
March 08, 2023 13:27 ET
|
NKGen Biotech
SANTA ANA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
January 10, 2023 13:27 ET
|
NKGen Biotech
SANTA ANA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies,...
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease
November 04, 2022 12:35 ET
|
NKGen Biotech
SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
October 17, 2022 14:27 ET
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma
September 21, 2022 13:09 ET
|
NKGen Biotech
SANTA ANA, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell...
NKGen Biotech to Present at the Baird 2022 Global Healthcare Conference
September 07, 2022 14:00 ET
|
NKGen Biotech
SANTA ANA, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022
September 06, 2022 14:37 ET
|
NKGen Biotech
SANTA ANA, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
Alphageneron to Participate in Cell Therapy Durability Response Summit
August 17, 2022 10:30 ET
|
Alphageneron Pharmaceuticals
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a clinical stage pharmaceutical company developing a diverse platform of...